

# Survival from childhood cancer in Kampala, Uganda

Biying Liu<sup>1</sup>  | Danny R. Youlden<sup>2,3</sup>  | Henry Wabinga<sup>4</sup> | Sarah Nambooze<sup>5</sup> |  
Phoebe Mary Amulen<sup>5</sup> | Joanne F. Aitken<sup>2,3</sup> | Donald Maxwell Parkin<sup>6,7</sup> 

<sup>1</sup> African Cancer Registry Network, INCTR, Oxford, UK

<sup>2</sup> Cancer Council Queensland, Brisbane, Australia

<sup>3</sup> School of Public Health, The University of Queensland, Brisbane, Queensland, Australia

<sup>4</sup> Department of Pathology, College of Health Sciences, Makerere University, Kampala, Uganda

<sup>5</sup> Kampala Cancer Registry, College of Health Sciences, Makerere University, Kampala, Uganda

<sup>6</sup> International Agency for Research on Cancer, Lyon, France

<sup>7</sup> Nuffield Department of Population health, University of Oxford, Oxford, UK

## Correspondence

Biying Liu, African Cancer Registry Network, INCTR, Prama House, Oxford, UK.  
Email: [bliu@afcrn.org](mailto:bliu@afcrn.org)

## Funding information

African Cancer Registry Network; National Childhood Cancer Registry project extensi; Fondation Sanofi Espoir; National Childhood Cancer Registration in Africa

## Abstract

Population-based data on survival from childhood cancers in sub-Saharan Africa are sparse. We report data on 221 children with cancer diagnosed between 2010 and 2014 in the population of Kampala, Uganda. Survival for eight of nine children with cancer assessed was below the WHO's global target of 60% (the exception was Hodgkin lymphoma: 86% at 3 years). There was significant ( $P < .05$ ) decline in survival between 1 and 3 years for Wilms tumour and Kaposi sarcoma (30% and 34% at 3 years, respectively). Survival from Burkitt lymphoma, Wilms tumour and Kaposi sarcoma has not changed compared with results from the 2005-2009 study.

## KEYWORDS

cancer, childhood, registry, survival, Uganda

## 1 | INTRODUCTION

With limited population-level data, it is difficult to understand the true burden and survival from childhood cancers in Africa, making effective planning for cancer management and control challenging. In 2018, we reported results of survival from four childhood cancers, diagnosed in residents of Kampala, Uganda in 2005-2009.<sup>1</sup> In this paper, we provide more recent survival data on the same four cancers (Burkitt lymphoma, retinoblastoma, Wilms tumour and Kaposi sarcoma [KS]) and on five other common cancers of childhood in this population.

Kampala Cancer Registry is a population-based cancer registry, collecting information on all cases of cancer diagnosed in residents of Kyadondo County (Kampala city and adjacent peri-urban area).<sup>2</sup> The data collected include contact details (including telephone number) of

the parents/next of kin of registered childhood cancer cases, allowing the possibility of follow-up after discharge from hospital.

## 2 | RESULTS

### 2.1 | Methods

Cases of cancer in children, of nine types (as defined by the two-character categories of the International Classification of Childhood Cancer, third edition [ICCC-3]<sup>3</sup>) for which 20 or more cases had been registered in 2010-2014, were included in the study. They were cases of acute lymphoid leukaemia (ALL - 1a in the ICCC), Hodgkin lymphoma (HL-2a), Burkitt lymphoma (BL-2c), non-Hodgkin lymphoma (excluding Burkitt) (other NHL-2b), retinoblastoma (5), Wilms tumour (6a), osteosarcoma (8a), rhabdomyosarcoma (9a) and KS (KS- 9c).

**Abbreviations:** KS, Kaposi sarcoma; NHL, non-Hodgkin lymphoma

## 2.1.1 | Follow-up

The closing date of the study was 31 December, 2017. The clinical records of cases whose status (alive or dead) was not known on this date were traced in hospital records and the date and status at last contact were updated. Cases whose status was still unknown were traced by direct contact, either by telephone or (rarely) home visits. Cases were excluded from the analysis if there was no information on follow up (date of diagnosis was the same as date of last follow-up).

## 2.1.2 | Statistical analysis

We used the semi-complete approach<sup>4</sup> to estimate survival at 1 and 3 years after diagnosis. We present the Ederer II relative survival estimates, prepared using the 'strs' commands in STATA version 14. Relative survival was calculated by cancer type, using population life tables derived using the method previously described by Joko-Fru et al.<sup>1</sup> For patients who remained alive, survival time was censored at either 3 years after diagnosis or the last known date of follow-up, whichever occurred first. Estimated survival and 95% confidence intervals (95% CIs) were reported for 1 and 3 years after diagnosis.

## 2.2 | Findings

Of a total 265 registered childhood cancer patients, 44 cancer cases (16.6%, ranging from 0% of ALL to 33% of NHL) were excluded due to lack of follow-up information after the date of diagnosis. The remaining 221 malignancies available for analysis are shown in Table 1, with the largest groups being KS (n = 42, 19%), Wilms tumour (n = 37, 17%) and Burkitt lymphoma (n = 35, 16%).

As shown in Table 1, there were nearly three times as many cases of acute lymphoblastic leukaemia in males compared with females (n = 14:5), and twice as many cases of Burkitt lymphoma (n = 24:11). Rhabdomyosarcoma was the only cancer with more female patients than males (n = 6:13).

Overall median follow-up time was 277 days (interquartile range = 54-1532 days). Just over half (n = 112, 51%) of the children in the study cohort died from any cause within 3 years of diagnosis. Of those whose status was last recorded as being alive, 55 of 109 (50%) were lost to follow-up before the end of the 3 years.

Relative survival at 3 years after diagnosis was 86% for Hodgkin lymphoma, but less than 60% for all other cancers (Table 2). Survival was poorest for Wilms tumours - 55% at one year and 30% at 3 years.

The decrease in survival between 1 and 3 years was significant only for Wilms and KS ( $P < .05$ ); the decline for osteosarcoma (81% at 1 year and 49% at 3 years) just failed to be significant ( $P = .15$ ).

Compared with the previous study (cases diagnosed in 2005-2009), survival at 1 year and at 3 years was higher in the present study for three of the four childhood cancers with comparable data (all except for KS at 3 years) (Table 2). However, in all instances the number of cases

**TABLE 1** Study cohort by type of cancer and selected characteristics

Characteristic	Acute lym- phoblastic leukaemia		Hodgkin lymphoma		Non- Hodgkin lymphoma		Burkitt lymphoma		Retino blastoma		Wilms tumour		Osteo sarcoma		Rhabdomyo sarcoma		Kaposi sarcoma	
	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %
Total	19		16		18		35		21		37		14		19		42	
Sex ratio (male:female)	14:5		10:6		11:7		24:11		11:10		20:17		7:7		6:13		24:18	
Age group at diagnosis	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %	n	Col %
0-4 years	7	37%	4	25%	7	39%	14	40%	14	67%	25	68%	0	0%	5	26%	14	33%
5-9 years	6	32%	5	31%	8	44%	13	37%	5	24%	10	27%	4	29%	9	47%	9	21%
10-15 years	6	32%	7	44%	3	17%	8	23%	2	10%	2	5%	10	71%	5	26%	19	45%

**TABLE 2** One- and 3-year relative survival by type of cancer, and P-value comparing 1- and 3-year relative survival for 2010-2014

Type of cancer	Relative survival (95% CI)				P
	Kampala 2005-2009*		Kampala 2010-2014		
	1-year	3-years	1-year	3-years	
ALL	-	-	57 (32, 76)	46 (23, 67)	.49
HL	-	-	94 (61, 99)	86 (52, 97)	.48
NHL	-	-	58 (31, 77)	42 (17, 65)	.37
BL	58 (41, 72)	44 (27, 60)	59 (39, 74)	54 (33, 71)	.69
Retinoblastoma	43 (16, 69)	N.A.	63 (38, 81)	57 (31, 76)	.67
Wilms tumour	41 (18, 63)	17 (3, 41)	55 (37, 70)	30 (15, 47)	.04
Osteosarcoma	-	-	81 (43, 95)	49 (12, 79)	.15
Rhabdomyosarcoma	-	-	60 (34, 79)	54 (28, 74)	.69
Kaposi sarcoma	54 (32, 71)	36 (17, 56)	59 (43, 72)	34 (20, 49)	.02

\*Source: Joko-Fru et al (2018)<sup>1</sup>.

Abbreviations: ALL, acute lymphoblastic leukaemia; BL, Burkitt lymphoma; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma. Brackets indicate 95% confidence interval.

available for analysis was small and confidence intervals were wide; there was no statistical difference between the results from the two periods.

Survival at 3 years was not available for cases of retinoblastoma in the previous study. One year after diagnosis, survival in the current study was higher (63% vs 43%) but confidence intervals were wide and the difference was nonsignificant.

### 3 | DISCUSSION

Childhood cancer is generally not preventable but more than 80% of paediatric cancer cases are curable. In 2018, WHO launched the Global Initiative for Childhood Cancer to help countries to achieve at least 60% survival for all children with cancer globally by 2030.<sup>5,6</sup> Compared with this goal, our findings reveal the areas where more efforts are needed to close the gap. At 3 years, only survival from Hodgkin lymphoma remained above 60% (85%). Survival for all of the other eight malignancies examined here was less than 60%, and, in the case of Wilms tumour and KS, it was much less than 50% (30% and 34%, respectively).

Our findings are similar to a recently published study from the largest hospital in Blantyre, Malawi,<sup>7</sup> which found that the combined observed survival at the end of treatment of 53% for five common childhood cancers, within a 2-year period. Note that 19% of the patients in this Malawi cohort abandoned treatment.<sup>7</sup> A hospital-based study from South Africa<sup>8</sup> described overall 5-year survival for retinoblastoma of 58%, similar to the 3-year estimate of 57% for Kampala as reported here.

In the present study, there was no significant difference in survival at 1 and 3 years post-diagnosis, except for Wilms tumour and KS ( $P < .1$ ). Mutyaba et al<sup>9</sup> noted that a high percentage (more than one-third) of patients did not complete treatment for these cancers by the end of first year after diagnosis, with 1-year survival of 44% for Wilms tumour

and 67% for KS, consistent with our 1-year survival results for these two cancers. The French African Paediatric Oncology Group Study found 3-year observed survival of 72% for Wilms tumour patients aged 6 months to 17 years across seven sub-Saharan facilities.<sup>10</sup>

The best survival in our study was for cases of Hodgkin lymphoma (86% at 3 years), similar to the findings in a multi-centre study from South Africa,<sup>8</sup> which reported 5-year observed survival of 79% among Hodgkin lymphoma patients. We found 57% (95% CI 32-76) of children with acute leukaemia alive 1 year after diagnosis, compared with only 20% of children admitted to the Uganda Cancer Institute in 2006-2009<sup>9</sup>; survival of children with Burkitt lymphoma was, however, comparable (a 1-year survival of 59% and 55%, respectively).

### 4 | CONCLUSIONS

Data on survival for population-based series of childhood cancers are very sparse for Africa, and confirm the very poor survival compared with that from high-income countries. Our results from two time periods (2005-2009 and 2010-2014) provide a benchmark against which progress in the results from earlier detection and treatment can be evaluated. Such studies should be replicated in other sub-Saharan Africa countries wherever possible.

### ACKNOWLEDGMENTS

We acknowledge the all the hospital staff who have helped with case finding and data collection in the Kampala Cancer Registry.

The majority of the data studied were collected during a research project titled National Childhood Cancer Registration in Africa (2017-2018), under the My Child Matters initiative, funded by the Sanofi Espoir Foundation. During the later phase of the study, African Cancer Registry Network has funded for extra data abstraction and data cleaning.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request. All data requests will be evaluated by the AFCRN research committee. Details of the data application process are outlined on the AFCRN website (<http://afcrn.org/index.php/research/how-to-apply/76-research-collaborations>).

## ORCID

Biying Liu  <https://orcid.org/0000-0003-3438-683X>

Danny R. Youlden  <https://orcid.org/0000-0002-2721-9083>

Donald Maxwell Parkin  <https://orcid.org/0000-0002-3229-1784>

## REFERENCES

- Joko-Fru WY, Parkin DM, Borok M, et al. Survival from childhood cancers in Eastern Africa: a population-based registry study. *Int J Cancer*. 2018;143(10):2409-2415.
- Parkin DM, Ferlay J, Jemal A, eds. *Cancer in sub-Saharan Africa*. IARC Scientific Publications No 167. Lyon: International Agency for Research on Cancer; 2018. <https://publications.iarc.fr/Book-And-Report-Series/IARC-Scientific-Publications/Cancer-In-Sub-Saharan-Africa-2018>.
- Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. *Cancer*. 2005;103:1457-1467.
- Brenner H, Swaminathan R. Statistical methods for cancer survival analysis introduction and background. <http://survcan.iarc.fr/survival/chap2.pdf>. Accessed March 16, 2018.
- World Health Organisation. Cancer in children. 2018. <https://www.who.int/news-room/fact-sheets/detail/cancer-in-children>. Accessed August 18, 2020.
- Piñeros M, Mery L, Soerjomataram I, Bray F, Steliarova-Foucher E. Scaling up the surveillance of childhood cancer: a global roadmap. *J Natl Cancer Inst*. 2020. <https://doi.org/10.1093/jnci/djaa069>
- Chakumatha E, Weijers J, Banda K, et al. Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. *Pediatr Blood Cancer*. 2020;67:e28322.
- Mutyaba I, Wabinga HR, Orem J, Casper C, Phipps W. Presentation and Outcomes of Childhood Cancer Patients at Uganda Cancer Institute. *Glob Pediatr Health*. 2019;6. <https://doi.org/10.1177/2333794X19849749>.
- Goolam S, Kana H, Welsh N, Wainwright L, Poole J, Mayet I. A 20-year retrospective review of retinoblastoma at two tertiary academic hospitals in Johannesburg, South Africa. *Ocul Oncol Pathol*. 2018;4:170-175.
- Yao AJ, Moreira C, Traore F, et al. Treatment of Wilms tumor in Sub-Saharan Africa: results of the Second French African Pediatric Oncology Group Study. *J Glob Oncol*. 2019;5:1-8.

**How to cite this article:** Liu B, Youlden DR, Wabinga H, et al. Survival from childhood cancer in Kampala, Uganda. *Pediatr Blood Cancer*. 2021;68:e28876. <https://doi.org/10.1002/psc.28876>